Print

Johnson & Johnson (JNJ)'s Kris Curry and Novartis AG (NVS)' Cynthia Cetani to Chair PCC 2013: CBI's 10th Annual Pharmaceutical Compliance Congress  
9/26/2012 9:44:30 AM

BOSTON, Sept. 26, 2012 /PRNewswire/ -- CBI is pleased to announce the Congress Co-Chairs for PCC 2013 CBI's 10th Annual Pharmaceutical Compliance Congress, taking place January 29-30, 2013 at the Ritz-Carlton in Washington, DC. The Congress is the premier compliance meeting for life sciences executives. PCC unites Chief Compliance Officers and their industry compliance, legal and regulatory peers to benchmark and share best practices and innovative approaches for successful corporate compliance programs.

This year's Congress Co-Chairs are Kris Curry, Vice President, Health Care Compliance, Pharmaceuticals Group, Johnson & Johnson and Cynthia "Cindy" Cetani, Vice President, Ethics & Compliance and Chief Compliance Officer, Novartis Pharmaceuticals Corporation. Curry and Cetani take the reins in 2013 from past Congress Chairs, including Doug Lankler, Executive Vice President and Chief Compliance and Risk Officer, Pfizer, and Michael Shaw, Vice President and Chief Compliance Officer, North America Pharmaceuticals, GlaxoSmithKline.

Curry is the global leader of Johnson & Johnson Pharmaceuticals' Health Care Compliance Program. She is recognized by her colleagues and peers as a results-oriented leader with demonstrated ability to implement large-scale project improvements that drive efficiencies and reduce overall costs. She has a reputation for building and developing high-performing teams with versatile and diverse experiences.

Cetani is Vice President and Chief Compliance Officer at Novartis Pharmaceuticals. In this role, she oversees the company's Corporate Compliance Program and, coordinating with the legal department, is responsible for establishing standards and policies pertaining to regulatory requirements to help ensure legal, ethical and proper conduct.

PCC boasts an executive-level industry speaking faculty, including representation from Auxilium, Biogen Idec, Boehringer Ingelheim, Celgene, Dendreon, Incyte, Ipsen, Meda, Medicis, Par, Pfizer, Purdue, Sunovion, Takeda, Teva, UCB and Vertex, as well as government perspectives from the DOJ, CMS and FDA.

Attendees will customize their Congress experience by choosing various breakout sessions, interactive workshops and concurrent tracks surrounding all aspects of corporate compliance, including:

  • Fraud and Abuse
  • Global Anti-Bribery / Anti-Corruption
  • Promotional / Social Media Compliance
  • Off-Label Risk Areas
  • Sunshine Requirements / Aggregate Spend Processes
  • Field Monitoring and Investigative Practices
  • Effective Communication and Training Programs
  • Clinical Investigator and CRO Compliance Oversight

CBI's Compliance Congress is the pharmaceutical industry's premier meeting place for cutting-edge content, valuable networking and unparalleled programming. For more information on the conference or to download the brochure, please visit www.cbinet.com/pcc .

About CBI:
CBI, an Advanstar company, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. For more information, please visit www.cbinet.comorcontact Emily Forest, Marketing Manager at emily.forest@cbinet.com or 339-298-2156.


This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE The Center for Business Intelligence


//-->